非小细胞肺癌治疗药物——埃万妥单抗  

A novel drug for treatment of non-small cell lung cancer: amivantamab

作　　者：陈敏 王茜[1] 方翼[1] CHEN Min;WANG Qian;FANG Yi(Clinical Trial Institution,Peking University People's Hospital,Beijing 100044,China;Department of Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China)

机构地区：[1]北京大学人民医院临床试验机构,北京100044 [2]北京大学医学部药学院药事管理与临床药学系,北京100191

出　　处：《临床药物治疗杂志》2023年第2期27-30,共4页Clinical Medication Journal

摘　　要：埃万妥单抗是一种可同时靶向表皮生长因子受体(EGFR)和细胞间质上皮转换因子的双特异性抗体,2021年5月21日由FDA批准上市。埃万妥单抗是EGFR外显子20插入突变非小细胞肺癌成人患者的首款靶向药物,研究表明埃万妥单抗在该类患者中的疗效显著,是表皮生长因子受体酪氨酸激酶抑制剂(EGFRTKIs)耐药患者的潜在治疗策略之一。本文主要针对埃万妥单抗治疗非小细胞肺癌的作用机制、药动学、临床疗效、安全性及最新研究进展等进行综述,旨在为EGFR-TKIs耐药患者的创新治疗提供参考。Amivantamab, a bispecific antibody targeting both epidermal growth factor receptor(EGFR) and cellular-mesenchymal epithelial transition factor(c-MET), was approved for marketing by the FDA on May 21, 2021. Amivantamab is the first targeted therapy for subset of adult patients with non-small cell lung cancer, whose tumors have specific types of genetic mutations: EGFR exon 20 insertion mutations. Clinical studies have shown that amivantamab has significant efficacy in its indicated population and is one of the potential treatment strategies for patients with epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) resistance. In order to further deepen the understanding of amivantamab for clinical practitioners, this paper mainly reviewed the mechanism of action, pharmacokinetics, efficacy, safety and immunogenicity of amivantamab in the treatment of non-small cell lung cancer, and summarized the latest research progress.

关 键 词：埃万妥单抗 非小细胞肺癌 双特异性抗体 疗效 安全性 

分 类 号：R979.1[医药卫生—药品]